Cover Image
市場調查報告書

白塞病:開發中產品分析

Behcet Disease - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361617
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
白塞病:開發中產品分析 Behcet Disease - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 65 Pages
簡介

白塞病(或稱貝歇氏症候群(Behcet's syndrome)),是罕見的免疫介在性全身性血管炎。一般症狀有口內及生殖器的潰瘍。惡化後的症狀有眼和身體其他部分發炎(腫,熱、皮膚發紅,疼痛等)。治療的目的為緩解疼痛,防止症狀惡化。

本報告提供白塞病的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

白塞病概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發中產品
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

白塞病的治療藥開發企業

  • AbbVie Inc
  • Celgene Corp
  • Cell Medica Ltd
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • Novartis AG
  • Panacea Biotec Ltd
  • R Pharm

藥物簡介

白塞病:暫停中的計劃

白塞病:開發中止的產品

白塞病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9302IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.

Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behcet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 1, 2, 3, 1 and 1 respectively.

Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Behcet Disease - Overview
    • Behcet Disease - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Behcet Disease - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Behcet Disease - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Celgene Corp
    • Cell Medica Ltd
    • Coherus BioSciences Inc
    • Genor BioPharma Co Ltd
    • Novartis AG
    • Panacea Biotec Ltd
    • R Pharm
  • Behcet Disease - Drug Profiles
    • adalimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • apremilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infliximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Behcet Disease - Dormant Projects
  • Behcet Disease - Discontinued Products
  • Behcet Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir
      • Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet
      • Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine
      • Apr 14, 2015: Delenex Announces New Clinical Data
      • Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR
      • May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet's Disease For Humira Pre-filled Syringe In Japan
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Behcet Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Behcet Disease - Pipeline by AbbVie Inc, H1 2017
  • Behcet Disease - Pipeline by Celgene Corp, H1 2017
  • Behcet Disease - Pipeline by Cell Medica Ltd, H1 2017
  • Behcet Disease - Pipeline by Coherus BioSciences Inc, H1 2017
  • Behcet Disease - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Behcet Disease - Pipeline by Novartis AG, H1 2017
  • Behcet Disease - Pipeline by Panacea Biotec Ltd, H1 2017
  • Behcet Disease - Pipeline by R Pharm, H1 2017
  • Behcet Disease - Dormant Projects, H1 2017
  • Behcet Disease - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Behcet Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top